Showing results (31-40 of 152) with videos related to

Sort By:
Pageof 16
Plos One|August 31, 2018
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosisNaim Alkhouri, Casey Johnson, Leon Adams, et al.
Journal of Hepatology|June 24, 2023
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver diseaseManuel Romero-Gómez, Eric Lawitz, R Ravi Shankar, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2013
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis CZobair M Younossi, Maria Stepanova, Linda Henry, et al.
Plos One|October 5, 2018
Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosisNaim Alkhouri, Casey Johnson, Leon Adams, et al.
Gastro Hep Advances|June 15, 2026
Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation SystemNaim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, et al.
Antiviral Therapy|June 28, 2016
Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studiesEric Lawitz, Fred Poordad, Robert H Hyland, et al.
Hepatology (Baltimore, Md.)|August 20, 2010
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis CFred Poordad, Eric Lawitz, Mitchell L Shiffman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2012
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infectionElliot B Tapper, Eric B Cohen, Keyur Patel, et al.
Nature Communications|November 6, 2023
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitisPhilip N Newsome, Arun J Sanyal, Guy Neff, et al.
The Lancet. Gastroenterology & Hepatology|July 15, 2026
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trialRohit Loomba, Jacob George, Laurent Castera, et al.
Pageof 16